A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults

ClinicalTrials.gov ID: NCT05972174

Public ClinicalTrials.gov record NCT05972174. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1/2, Randomized, Observer-Blind, Parallel, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults ≥18 Years of Age

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this Phase 1/2 study is to generate sufficient safety and immunogenicity data of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large Phase 3 trial with one selected vaccine candidate. The study will be conducted in 2 Parts (Part A and Part B) that will enroll and run concurrently. Part A of the study will evaluate 4 vaccine candidates (H5N8, H7N9, H5 only, and H7 only). Part B of the study will evaluate a single vaccine candidate (H5 only-CG).

Study identification

NCT ID: NCT05972174
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: ModernaTX, Inc.; Industry
Enrollment: 1,504 participants

Conditions and interventions

Conditions

Influenza

Interventions

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 10, 2023 (Actual)
Primary completion: Jul 16, 2024 (Actual)
Completion: Jul 16, 2024 (Actual)
Last update posted: Jul 16, 2025

2023 – 2024

United States locations

U.S. sites: 9
U.S. states: 8
U.S. cities: 9

Facility	City	State	ZIP	Site status
CenExel RCA	Hollywood	Florida	33024	—
Velocity Clinical Research	Savannah	Georgia	31406	—
Johnson County Clin-Trials	Lenexa	Kansas	66219	—
DM Clinical Research	Southfield	Michigan	48076	—
Velocity Clinical Research	Lincoln	Nebraska	68510	—
Velocity Clinical Research Providence	East Greenwich	Rhode Island	02818	—
DM Clinical Research	Sugar Land	Texas	77478	—
DM Clinical Research	Tomball	Texas	77375	—
J. Lewis Research, Inc/Jordan River Family Medicine	South Jordan	Utah	84095	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05972174, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 16, 2025 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05972174 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →